
Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm
Positive results from phase 3 RATIONALE-306 trial (NCT03783442), as well as its unique mechanism of action, position tislelizumab-jsgr (Tevimbra) as an optimal agent when combined with chemotherapy for patients with treatment-naive esophageal squamous cell …